AstraZeneca announces three large-scale initiatives in China to advance global medicine research and development
- Details
- Category: AstraZeneca
AstraZeneca announced three large-scale initiatives to build on the Company's long-standing commitment to China and advance global research and development (R&D) for innovative new medicines. The announcements made at the 2nd annual China International Import Expo (CIIE) in Shanghai include the creation of a new Global R&D Centre and an artificial intelligence (AI) Innovation Centre, both in Shanghai, and the creation of a first-of-its-kind Healthcare Industrial Fund with China International Capital Corporation Limited (CICC).
Abbott announces discovery of new strain of HIV, keeping global health community a step ahead of the virus
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced today that a team of its scientists identified a new subtype of the human immunodeficiency virus (HIV), called HIV-1 Group M, subtype L.(1) The findings, published today in the Journal of Acquired Immune Deficiency Syndromes (JAIDS), show the role next-generation genome sequencing is playing in helping researchers stay one step ahead of mutating viruses and avoiding new pandemics.
Novartis Cosentyx® shows encouraging results versus Humira® from first-of-its-kind head-to-head trial in psoriatic arthritis
- Details
- Category: Novartis
Novartis, a leader in rheumatology and immuno-dermatology, announced results from the EXCEED head-to-head trial comparing Cosentyx® (secukinumab) to Humira®* (adalimumab) in patients with active psoriatic arthritis (PsA)[1]. While Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, it showed numerically higher results versus Humira®*[1].
Bristol-Myers Squibb awards "Golden Tickets" for LabCentral to Carmine Therapeutics, STIMIT
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life sciences and biotech startups, today announced that Carmine Therapeutics and STIMIT are the winners of Bristol-Myers Squibb's 2019 Golden Tickets for LabCentral.
Boehringer Ingelheim advances first pan-KRAS inhibitor BI 1701963 into clinical testing
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim presented promising preclinical data from its pan-KRAS program including the novel, oral inhibitor BI 1701963 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, USA(1). Based on these results the compound has been advanced to Phase I clinical testing alone and in combination with trametinib in patients with different types of advanced solid tumors with KRAS mutations.
AstraZeneca divests rights to Seroquel and Seroquel XR in Europe and Russia
- Details
- Category: AstraZeneca
AstraZeneca has agreed the sale and licence of the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia to Cheplapharm Arzneimittel GmbH (Cheplapharm). Seroquel and Seroquel XR, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in Europe and Russia.
OPKO and Pfizer announce positive Phase 3 top-line results for somatrogon
- Details
- Category: Pfizer
OPKO Health Inc. (NASDAQ: OPK) and Pfizer Inc. (NYSE: PFE) announced that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with growth hormone deficiency (GHD) met its primary endpoint of non-inferiority to daily GENOTROPIN® (somatropin) for injection, as measured by annual height velocity at 12 months.
More Pharma News ...
- Amgen recommends rejection of 'mini-tender' offer from TRC Capital Corporation
- Bayer launches LifeHub UK focused on artificial intelligence to optimize data-driven drug discovery and disease diagnosis
- Nplate® (romiplostim) now approved for earlier use in adults with immune thrombocytopenia
- The Bristol-Myers Squibb-Pfizer Alliance and Fitbit collaborate to address gaps in atrial fibrillation detection with the aim of accelerating diagnosis
- Trastuzumab deruxtecan granted FDA Priority Review for treatment of patients with HER2-positive metastatic breast cancer
- Novartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host disease
- Sanofi opens its first digitally-enabled, continuous manufacturing facility; ushers in next generation of biotech manufacturing